Search

Your search keyword '"Bolcen, Shanna"' showing total 13 results
Start Over Author "Bolcen, Shanna" Publication Year Range Last 10 years
13 results on '"Bolcen, Shanna"'

1. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination

Author

Zhou, Zhao-Hua, Cortese, Margaret M., Fang, Jia-Long, Wood, Robert, Hummell, Donna S., Risma, Kimberly A., Norton, Allison E., KuKuruga, Mark, Kirshner, Susan, Rabin, Ronald L., Agarabi, Cyrus, Staat, Mary A., Halasa, Natasha, Ware, Russell E., Stahl, Anna, McMahon, Maureen, Browning, Peter, Maniatis, Panagiotis, Bolcen, Shanna, Edwards, Kathryn M., Su, John R., Dharmarajan, Sai, Forshee, Richard, Broder, Karen R., Anderson, Steven, and Kozlowski, Steven

Published
2023
Full Text
View/download PDF

2. Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides

Author

Le Doare, Kirsty, primary, Gaylord, Michelle A., additional, Anderson, Annaliesa S., additional, Andrews, Nick, additional, Baker, Carol J., additional, Bolcen, Shanna, additional, Felek, Arif, additional, Giardina, Peter C., additional, Grube, Christopher D., additional, Hall, Tom, additional, Hallis, Bassam, additional, Izu, Alane, additional, Madhi, Shabir A., additional, Maniatis, Pete, additional, Matheson, Mary, additional, Mawas, Fatme, additional, McKeen, Andrew, additional, Rhodes, Julia, additional, Alston, Bailey, additional, Patel, Palak, additional, Schrag, Stephanie, additional, Simon, Raphael, additional, Tan, Charles Y., additional, Taylor, Stephen, additional, Kwatra, Gaurav, additional, and Gorringe, Andrew, additional

Published
2024
Full Text
View/download PDF

3. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel

Author

Lester, Sandra N., primary, Stumpf, Megan, additional, Freeman, Brandi D., additional, Mills, Lisa, additional, Schiffer, Jarad, additional, Semenova, Vera, additional, Jia, Tao, additional, Desai, Rita, additional, Browning, Peter, additional, Alston, Bailey, additional, Ategbole, Muyiwa, additional, Bolcen, Shanna, additional, Chen, Alexander, additional, David, Ebenezer, additional, Manitis, Panagiotis, additional, Tatum, Heather, additional, Qin, Yunlong, additional, Zellner, Briana, additional, Drobeniuc, Jan, additional, Tejada-Strop, Alexandra, additional, Chatterjee, Payel, additional, Shrivastava-Ranjan, Punya, additional, Jenks, M. Harley, additional, McMullan, Laura K., additional, Flint, Mike, additional, Spiropoulou, Christina F., additional, Niemeyer, Glenn P., additional, Werner, Bonnie J., additional, Bean, Christopher J., additional, Johnson, Jeffrey A., additional, Hoffmaster, Alex R., additional, Satheshkumar, Panayampalli S., additional, Schuh, Amy J., additional, Owen, S. Michele, additional, and Thornburg, Natalie J., additional

Published
2024
Full Text
View/download PDF

4. Development of A Standardized Opsonophagocytosis Killing Assay for Group B Streptococcus and Assessment in an Interlaboratory Study

Author

Leung, Stephanie, primary, Collett, Clare F., additional, Allen, Lauren, additional, Lim, Suzanna, additional, Maniatis, Pete, additional, Bolcen, Shanna J., additional, Alston, Bailey, additional, Patel, Palak Y., additional, Kwatra, Gaurav, additional, Hall, Tom, additional, Thomas, Stephen, additional, Taylor, Stephen, additional, Le Doare, Kirsty, additional, and Gorringe, Andrew, additional

Published
2023
Full Text
View/download PDF

5. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel

Author

Lester, Sandra N., primary, Stumpf, Megan, additional, Freeman, Brandi D., additional, Mills, Lisa, additional, Schiffer, Jarad, additional, Semenova, Vera, additional, Jia, Tao, additional, Desai, Rita, additional, Browning, Peter, additional, Alston, Bailey, additional, Ategbole, Muyiwa, additional, Bolcen, Shanna, additional, Chen, Alexander, additional, David, Ebenezer, additional, Manitis, Panagiotis, additional, Tatum, Heather, additional, Qin, Yunlong, additional, Zellner, Briana, additional, Drobeniuc, Jan, additional, Tejada-Strop, Alexandra, additional, Chatterjee, Payel, additional, Shrivastava-Ranjan, Punya, additional, Jenks, M. Harley, additional, McMullan, Laura K., additional, Flint, Mike, additional, Spiropoulou, Christina F., additional, Niemeyer, Glenn P., additional, Werner, Bonnie J., additional, Bean, Christopher J., additional, Johnson, Jeffrey A., additional, Hoffmaster, Alex R., additional, Satheshkumar, Panayampalli S., additional, Schuh, Amy J., additional, Owen, S. Michele, additional, and Thornburg, Natalie J., additional

Published
2023
Full Text
View/download PDF

6. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination

Author

Zhou, Zhao-Hua, primary, Cortese, Margaret M., additional, Fang, Jia-Long, additional, Wood, Robert, additional, Hummell, Donna S., additional, Risma, Kimberly A., additional, Norton, Allison E., additional, KuKuruga, Mark, additional, Kirshner, Susan, additional, Rabin, Ronald L., additional, Agarabi, Cyrus, additional, Staat, Mary A., additional, Halasa, Natasha, additional, Ware, Russell, additional, Stahl, Anna, additional, McMahon, Maureen, additional, Browning, Peter, additional, Maniatis, Panagiotis, additional, Bolcen, Shanna, additional, Edwards, Kathryn M., additional, Su, John R., additional, Dharmarajan, Sai, additional, Forshee, Richard, additional, Broder, Karen R., additional, Anderson, Steven, additional, and Kozlowski, Steven, additional

Published
2023
Full Text
View/download PDF

7. Household Transmission and Symptomology of Severe Acute Respiratory Syndrome Coronavirus 2 Alpha Variant among Children—California and Colorado, 2021

Author

Waltenburg, Michelle A., primary, Whaley, Melissa J., additional, Chancey, Rebecca J., additional, Donnelly, Marisa A.P., additional, Chuey, Meagan R., additional, Soto, Raymond, additional, Schwartz, Noah G., additional, Chu, Victoria T., additional, Sleweon, Sadia, additional, McCormick, David W., additional, Uehara, Anna, additional, Retchless, Adam C., additional, Tong, Suxiang, additional, Folster, Jennifer M., additional, Petway, Marla, additional, Thornburg, Natalie J., additional, Drobeniuc, Jan, additional, Austin, Brett, additional, Hudziec, Meghan M., additional, Stringer, Ginger, additional, Albanese, Bernadette A., additional, Totten, Sarah E., additional, Matzinger, Shannon R., additional, Staples, J. Erin, additional, Killerby, Marie E., additional, Hughes, Laura J., additional, Matanock, Almea, additional, Beatty, Mark, additional, Tate, Jacqueline E., additional, Kirking, Hannah L., additional, Hsu, Christopher H., additional, Alford, Alexis, additional, Baird, Samuel, additional, Bankers, Laura, additional, Bello, Jazmin, additional, Bolcen, Shanna, additional, Browning, Peter, additional, Cook, Peter W., additional, David, Ebenezer, additional, Harcourt, Jennifer L., additional, Hareland, Geir, additional, Hetherington-Rauth, Molly C., additional, Ir, Diana, additional, Jain, Shilpi, additional, Jia, Tao Lily, additional, Johnson, Ralen, additional, Kelleher, Anna, additional, Kim, Gimin, additional, Li, Yan, additional, Lynch, Brian, additional, Mallal, Daniel, additional, Maniatis, Panagiotis, additional, Marine, Rachel, additional, Medrzycki, Magdalena, additional, Metz, John M., additional, Montmayeur, Anna Maria, additional, Moss, Kimberly M., additional, Justin Ng, Han Jia, additional, Nyugen, Van, additional, Ortiz, Kristina, additional, Paden, Clinton R., additional, Park, So Hee, additional, Queen, Krista, additional, Rossheim, Alexandria E.B., additional, Semenova, Vera, additional, Shepard, Samuel S., additional, Tamin, Azaibi, additional, Tao, Ying, additional, Tejada-Strop, Alexandra, additional, Wong, Phili, additional, Zellner, Briana, additional, and Zhang, Jing, additional

Published
2022
Full Text
View/download PDF

8. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel

Author

Lester, Sandra N., primary, Stumpf, Megan, additional, Freeman, Brandi D., additional, Mills, Lisa, additional, Schiffer, Jarad, additional, Semenova, Vera, additional, Jia, Tao, additional, Desai, Rita, additional, Browning, Peter, additional, Alston, Bailey, additional, Ategbole, Muyiwa, additional, Bolcen, Shanna, additional, Chen, Alexander, additional, David, Ebenezer, additional, Manitis, Panagiotis, additional, Tatum, Heather, additional, Qin, Yunlong, additional, Zellner, Briana, additional, Drobeniuc, Jan, additional, Tejada-Strop, Alexandra, additional, Chatterjee, Payel, additional, Shrivastava-Ranjan, Punya, additional, Jenks, M. Harley, additional, McMullan, Laura K., additional, Flint, Mike, additional, Spiropoulou, Christina F., additional, Niemeyer, Glenn P., additional, Werner, Bonnie J., additional, Bean, Christopher J., additional, Johnson, Jeffrey A., additional, Hoffmaster, Alex R., additional, Satheshkumar, Panayampalli S., additional, Schuh, Amy J., additional, Owen, S. Michele, additional, and Thornburg, Natalie J., additional

Published
2022
Full Text
View/download PDF

9. Isolation of Onchocerca lupi in dogs and black flies, California, USA

Author

Hassan, Hassan K., Bolcen, Shanna, Kubofcik, Joseph, Nutman, Thomas B., Eberhard, Mark L., Middleton, Kelly, Wekesa, Joseph Wakoli, Ruedas, Gimena, Nelson, Kimberly J., Dubielzig, Richard, De Lombaert, Melissa, Silverman, Bruce, Schorling, Jamie J., Adler, Peter H., Unnasch, Thomas R., and Beeler, Emily S.

Subjects
Cytochrome oxidase -- Analysis -- Health aspects, Dogs -- Analysis -- Health aspects, RNA -- Analysis -- Health aspects, Health
Abstract

Onchocerca lupi is a zoonotic parasite capable of infecting dogs, cats, and humans. Human infection was first suspected in 2002, when a case of human subconjunctival filariasis was found to [...]

Published
2015
Full Text
View/download PDF

10. Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020

Author

Basavaraju, Sridhar V, primary, Patton, Monica E, additional, Grimm, Kacie, additional, Rasheed, Mohammed Ata Ur, additional, Lester, Sandra, additional, Mills, Lisa, additional, Stumpf, Megan, additional, Freeman, Brandi, additional, Tamin, Azaibi, additional, Harcourt, Jennifer, additional, Schiffer, Jarad, additional, Semenova, Vera, additional, Li, Han, additional, Alston, Bailey, additional, Ategbole, Muyiwa, additional, Bolcen, Shanna, additional, Boulay, Darbi, additional, Browning, Peter, additional, Cronin, Li, additional, David, Ebenezer, additional, Desai, Rita, additional, Epperson, Monica, additional, Gorantla, Yamini, additional, Jia, Tao, additional, Maniatis, Panagiotis, additional, Moss, Kimberly, additional, Ortiz, Kristina, additional, Park, So Hee, additional, Patel, Palak, additional, Qin, Yunlong, additional, Steward-Clark, Evelene, additional, Tatum, Heather, additional, Vogan, Andrew, additional, Zellner, Briana, additional, Drobeniuc, Jan, additional, Sapiano, Matthew R P, additional, Havers, Fiona, additional, Reed, Carrie, additional, Gerber, Susan, additional, Thornburg, Natalie J, additional, and Stramer, Susan L, additional

Published
2020
Full Text
View/download PDF

11. Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020.

Author

Basavaraju, Sridhar V, Patton, Monica E, Grimm, Kacie, Rasheed, Mohammed Ata Ur, Lester, Sandra, Mills, Lisa, Stumpf, Megan, Freeman, Brandi, Tamin, Azaibi, Harcourt, Jennifer, Schiffer, Jarad, Semenova, Vera, Li, Han, Alston, Bailey, Ategbole, Muyiwa, Bolcen, Shanna, Boulay, Darbi, Browning, Peter, Cronin, Li, and David, Ebenezer

Subjects
SARS-CoV-2, IMMUNOGLOBULINS, SERODIAGNOSIS, BLOOD collection, CELL receptors, ENZYME-linked immunosorbent assay, DESCRIPTIVE statistics
Abstract

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in December 2019, with subsequent worldwide spread. The first US cases were identified in January 2020. Methods To determine if SARS-CoV-2–reactive antibodies were present in sera prior to the first identified case in the United States on 19 January 2020, residual archived samples from 7389 routine blood donations collected by the American Red Cross from 13 December 2019 to 17 January 2020 from donors resident in 9 states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at the Centers for Disease Control and Prevention for anti–SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan-Ig) enzyme-linked immunosorbent assay (ELISA) against the full spike protein were tested by IgG and IgM ELISAs, microneutralization test, Ortho total Ig S1 ELISA, and receptor-binding domain/ACE2 blocking activity assay. Results Of the 7389 samples, 106 were reactive by pan-Ig. Of these 106 specimens, 90 were available for further testing. Eighty-four of 90 had neutralizing activity, 1 had S1 binding activity, and 1 had receptor-binding domain/ACE2 blocking activity >50%, suggesting the presence of anti–SARS-CoV-2–reactive antibodies. Donations with reactivity occurred in all 9 states. Conclusions These findings suggest that SARS-CoV-2 may have been introduced into the United States prior to 19 January 2020. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

12. Isolation ofOnchocerca lupiin Dogs and Black Flies, California, USA

Author

Hassan, Hassan K., primary, Bolcen, Shanna, additional, Kubofcik, Joseph, additional, Nutman, Thomas B., additional, Eberhard, Mark L., additional, Middleton, Kelly, additional, Wekesa, Joseph Wakoli, additional, Ruedas, Gimena, additional, Nelson, Kimberly J., additional, Dubielzig, Richard, additional, De Lombaert, Melissa, additional, Silverman, Bruce, additional, Schorling, Jamie J., additional, Adler, Peter H., additional, Unnasch, Thomas R., additional, and Beeler, Emily S., additional

Published
2015
Full Text
View/download PDF

13. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel.

Author

Lester SN, Stumpf M, Freeman BD, Mills L, Schiffer J, Semenova V, Jia T, Desai R, Browning P, Alston B, Ategbole M, Bolcen S, Chen A, David E, Manitis P, Tatum H, Qin Y, Zellner B, Drobeniuc J, Tejada-Strop A, Chatterjee P, Shrivastava-Ranjan P, Jenks MH, McMullan LK, Flint M, Spiropoulou CF, Niemeyer GP, Werner BJ, Bean CJ, Johnson JA, Hoffmaster AR, Satheshkumar PS, Schuh AJ, Owen SM, and Thornburg NJ

Abstract

Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a novel human coronavirus that was identified in 2019. SARS-CoV-2 infection results in an acute, severe respiratory disease called coronavirus disease 2019 (COVID-19). The emergence and rapid spread of SARS-CoV-2 has led to a global public health crisis, which continues to affect populations across the globe. Real time reverse transcription polymerase chain reaction (rRT-PCR) is the reference standard test for COVID-19 diagnosis. Serological tests are valuable tools for serosurveillance programs and establishing correlates of protection from disease. This study evaluated the performance of one in-house enzyme linked immunosorbent assay (ELISA) utilizing the pre-fusion stabilized ectodomain of SARS-CoV-2 spike (S), two commercially available chemiluminescence assays Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Abbott SARS-CoV-2 IgG assay and one commercially available Surrogate Virus Neutralization Test (sVNT), GenScript USA Inc., cPass SARS-CoV-2 Neutralization Antibody Detection Kit for the detection of SARS-CoV-2 specific antibodies. Using a panel of rRT-PCR confirmed COVID-19 patients' sera and a negative control group as a reference standard, all three immunoassays demonstrated high comparable positivity rates and low discordant rates. All three immunoassays were highly sensitive with estimated sensitivities ranging from 95.4-96.6 %. ROC curve analysis indicated that all three immunoassays had high diagnostic accuracies with area under the curve (AUC) values ranging from 0.9698 to 0.9807. High positive correlation was demonstrated among the conventional microneutralization test (MNT) titers and the sVNT inhibition percent values. Our study indicates that independent evaluations are necessary to optimize the overall utility and the interpretation of the results of serological tests. Overall, we demonstrate that all serological tests evaluated in this study are suitable for the detection of SARS-CoV-2 antibodies., Competing Interests: ‘The author(s) declare that there are no conflicts of interest’. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Names of specific vendors, manufacturers, or products are included for public health and informational purposes; inclusion does not imply endorsement of the vendors, manufacturers, or products by the Centers for Disease Control and Prevention or the US Department of Health and Human Services.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results